ENVB

S-3 - Enveric Biosciences, Inc. (0000890821) (Filer)

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Director and CEO, Joseph Tucker, Ph.D., will participate in a panel discussion at Needham's upcoming Virtual Psychedelics Forum. The panel, "Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications," is scheduled for Monday, April 27, 1:00 PM - 2:00 PM ET. Event Details: Event: Needham's Virtual Psychedelics Forum Topic: Beyond TRD (Treatment-Resistant Depression): Non-Hallucinogens and New Indications Date & Time:

$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to an aggregate of 2,222,223 shares of common stock and short-term Series J warrants to purchase up to an agg

$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to an aggregate of 2,222,223 shares of common stock and short-term Series J warrants to purchase up to an aggregate of 2,222,223 shares of common stock, at a pu

DEFA14A - Enveric Biosciences, Inc. (0000890821) (Filer)

DEF 14A - Enveric Biosciences, Inc. (0000890821) (Filer)

PRE 14A - Enveric Biosciences, Inc. (0000890821) (Filer)

Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 ("the'232 patent") from the United States Patent and Trademark Office (USPTO) pertaining to its EVM301 Series of molecules. The EVM301 Series includes lead candidate, EB-003, being developed as potential treatments for mental health d

Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease Corporate and Business Development Highlights: Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) mol

10-K - Enveric Biosciences, Inc. (0000890821) (Filer)

8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

As a result of this action, there are no remaining challenges currently pending against Enveric's patent Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent) has been withdrawn. This action follows Enveric's filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending agai

Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects A recent independent Nature study reports that distinct signaling pathways support mechanistic separation of therapeutic benefit from hallucinations Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. Multiple independ

424B3 - Enveric Biosciences, Inc. (0000890821) (Filer)

EFFECT - Enveric Biosciences, Inc. (0000890821) (Filer)

D - Enveric Biosciences, Inc. (0000890821) (Filer)

S-1 - Enveric Biosciences, Inc. (0000890821) (Filer)

8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

424B5 - Enveric Biosciences, Inc. (0000890821) (Filer)

RCANN™ Trademark Portfolio Out-Licensed Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization of patented cannabinoid crème technology created by Enveric and intended for use in treatment of radiation dermatitis. The trademark license to TOTEC includes an option to purchase the RCANN trad

8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, the Company issued unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants have an exercise price of $4.16

424B5 - Enveric Biosciences, Inc. (0000890821) (Filer)

Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants will have an ex